Zobrazeno 1 - 10
of 117
pro vyhledávání: '"Jakob Dupont"'
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Externí odkaz:
https://doaj.org/article/641ceffdbc544edc932193e565ae7229
Autor:
Zishuo Ian Hu, Johanna C. Bendell, Andrea Bullock, Noelle K. LoConte, Hassan Hatoum, Paul Ritch, Hugo Hool, Joseph W. Leach, James Sanchez, Davendra P. S. Sohal, John Strickler, Ravindranath Patel, Andrea Wang‐Gillam, Irfan Firdaus, Kenneth H. Yu, Ann M. Kapoun, Eric Holmgren, Lei Zhou, Jakob Dupont, Vincent Picozzi, Vaibhav Sahai, Eileen M. O'Reilly
Publikováno v:
Cancer Medicine, Vol 8, Iss 11, Pp 5148-5157 (2019)
Abstract Purpose Notch signaling dysregulation is implicated in the development of pancreatic adenocarcinoma (PDAC). Tarextumab is a fully human IgG2 antibody that inhibits Notch2/3 receptors. Patients and Methods Aphase 2, randomized, placebo‐cont
Externí odkaz:
https://doaj.org/article/65d331d0de7c4b2799fe21f23c85e265
Autor:
Laura Carter, Andrea Wang-Gillam, Johanna Bendell, Wungki Park, Wells Messersmith, Drew Rasco, Lei Zhou, Jean-Marie Bruey, Beatrice Ferguson, Jakob Dupont, Marya Chaney, Johann De Bono, David Nickle, Anna Galkin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/4c3856eeaeb64d86ae0c6a78be6a0f14
Autor:
Jakob Dupont
Publikováno v:
Immuno Oncology Insights. 10:449-452
Autor:
Branimir Sikic, Jakob Dupont, Lu Xu, Ann M. Kapoun, Robert J. Stagg, Matthew A. Gubens, Rashmi Chugh, Georgy Manikhas, Peter D. Eisenberg, David C. Smith
Supplemental Figures 1-4. Supplemental Figure 1: Group Mean Concentration-Time Profiles and the Linear 2 Compartment Model Fit For Weekly Dosing Cohorts Supplemental Figure 2: Effect of Demcizumab on Hair Follicle Biomarkers Supplemental Figure 3: Ef
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::272b925e1d47105d29bfd08882fdc0a4
https://doi.org/10.1158/1078-0432.22457694.v1
https://doi.org/10.1158/1078-0432.22457694.v1
Autor:
Branimir Sikic, Jakob Dupont, Lu Xu, Ann M. Kapoun, Robert J. Stagg, Matthew A. Gubens, Rashmi Chugh, Georgy Manikhas, Peter D. Eisenberg, David C. Smith
Purpose: This phase I trial evaluated the safety, pharmacokinetics, and pharmacodynamics of demcizumab (OMP-21M18), a humanized IgG2 mAb targeting the Notch ligand DLL4 in adult patients with advanced malignancies.Experimental Design: Standard 3+3 de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3cde00993c39a6fb0037d43905375297
https://doi.org/10.1158/1078-0432.c.6523656
https://doi.org/10.1158/1078-0432.c.6523656
Autor:
Branimir Sikic, Jakob Dupont, Lu Xu, Ann M. Kapoun, Robert J. Stagg, Matthew A. Gubens, Rashmi Chugh, Georgy Manikhas, Peter D. Eisenberg, David C. Smith
Supplemental Tables 1-4. Supplemental Table 1: Treatment Emergent Adverse Events By Cohort (All Grades) Reported by >15% of Patients Supplemental Table 2: Pharmacokinetic NCA Parameters by Cohort Supplemental Table 3: Compartmental PK Analysis Final
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94ac4798261cb16576accc3190a38b90
https://doi.org/10.1158/1078-0432.22457691.v1
https://doi.org/10.1158/1078-0432.22457691.v1
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Resistance to immune checkpoint inhibitors (ICI) and other anticancer therapies is often associated with the accumulation of myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) in the tumor microenvironment (TME). Therefo
Autor:
Kenneth H. Yu, James Sanchez, Jakob Dupont, Hassan Hatoum, Noelle K. LoConte, Eric Holmgren, Zishuo Ian Hu, Davendra Sohal, Paul S. Ritch, Andrea Wang-Gillam, John H. Strickler, Ravindranath Patel, Irfan Firdaus, Hugo Hool, Lei Zhou, Ann M. Kapoun, Andrea J. Bullock, Johanna C. Bendell, Eileen M. O'Reilly, Vaibhav Sahai, Joseph W. Leach, Vincent J. Picozzi
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 8, Iss 11, Pp 5148-5157 (2019)
Cancer Medicine, Vol 8, Iss 11, Pp 5148-5157 (2019)
Purpose Notch signaling dysregulation is implicated in the development of pancreatic adenocarcinoma (PDAC). Tarextumab is a fully human IgG2 antibody that inhibits Notch2/3 receptors. Patients and methods Aphase 2, randomized, placebo-controlled, mul
A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors
Autor:
Anthony W. Tolcher, Kyriakos P. Papadopoulos, Rashmi Chugh, David Smith, Robert Joseph Stagg, Ann M. Kapoun, Amita Patnaik, Min Wang, Lu Xu, Jakob Dupont
Publikováno v:
Investigational New Drugs
Summary Purpose This Phase I trial evaluated the maximum tolerated dose, safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of tarextumab (OMP-5948), a novel cross-reactive antibody which binds and selectively inhibits signaling via